Genmab stock (DK0010272202): Analyst sentiment shifts as earnings forecasts decline

Genmab's consensus price target remains steady at kr.2,341 despite analyst downgrades to earnings estimates, signaling caution in the biotech sector.

Genmab A/S, a Danish antibody-focused biotechnology company, is facing mixed analyst sentiment as brokers have downgraded their earnings per share forecasts while maintaining their overall price targets, according to analyst estimates as of May 11, 2026. The consensus price target held steady at kr.2,341, with the most bullish analyst valuing the company at kr.3,046 per share and the most bearish at kr.1,400, reflecting significant divergence in market views.

As of: May 11, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Genmab A/S
• Sector/industry: Biotechnology, antibody-based therapeutics
• Headquarters/country: Denmark
• Core markets: Oncology and other disease areas
• Key revenue drivers: Antibody-based product candidates for cancer treatment
• Home exchange/listing venue: Nasdaq Copenhagen (GMAB); ADR on Nasdaq (GMAB)
• Trading currency: Danish Krone (DKK); USD for ADR

Genmab A/S: core business model

Genmab is an international biotechnology company focused on developing innovative antibody-based products and product candidates for the treatment of cancer and other diseases. The company's core purpose centers on improving patient outcomes through differentiated antibody therapeutics. With operations spanning Denmark and the United States—including a significant presence in Princeton, New Jersey—Genmab serves as a bridge between European biotech innovation and the US pharmaceutical market, making it relevant for American investors seeking exposure to specialized oncology therapeutics.

Main revenue and product drivers for Genmab

The company's revenue and pipeline are driven by its proprietary antibody platform and clinical-stage product candidates targeting oncology indications. Genmab's business model relies on advancing these candidates through clinical development while maintaining partnerships and licensing agreements that generate near-term revenue. The company's ability to translate its antibody technology into approved therapeutics remains central to investor interest and long-term value creation.

Analyst sentiment and earnings outlook

Recent analyst activity reveals a clear decline in sentiment following Genmab's latest results. While consensus price targets have remained unchanged at kr.2,341, the downward revision of earnings per share estimates suggests brokers are becoming more cautious about near-term profitability. This disconnect—stable price targets amid lower earnings forecasts—indicates that analysts may be pricing in longer development timelines or delayed revenue recognition, according to analyst consensus data as of May 11, 2026. The wide range between bullish and bearish valuations—kr.3,046 versus kr.1,400—underscores the uncertainty surrounding the company's pipeline and commercialization prospects.

Conclusion

Genmab remains a significant player in the antibody therapeutics space, with a pipeline focused on oncology and other disease areas. The recent downward revision of earnings estimates, despite stable price targets, reflects the inherent uncertainty in biotech development timelines and regulatory outcomes. For US investors, Genmab offers exposure to European biotech innovation through its Nasdaq-listed ADR, though the wide analyst valuation range suggests careful consideration of risk tolerance and investment horizon is warranted.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.